Tempus AI
TEM Nasdaq· Health Care Services
Last close · Oct 26, 2026
$67.16
KIRA · Stoqly’s AI analyst, in plain words
- Tempus AI had $1.3B of revenue in fiscal 2025, up 83.4% on the year before.
- Its operating margin was −19.9%, up 79.8 pts: of every 100 in sales, about −20 is left after running the business.
- Tempus AI lost $245M in fiscal 2025.
- Free cash flow was −$239M in fiscal 2025, −18.8% of revenue.
- Tempus AI returned $3.0M to shareholders in fiscal 2025. The diluted share count rose 45.4%.
- Tempus AI has $396M more cash than debt.
Market cap
$13.4M
P/E
—
Revenue
$1.3B
Net income
−$245M
Free cash flow
−$239M
Operating margin
−19.9%
Tempus AI in 30 seconds · fiscal 2025
Are sales growing?
+83.4%
Yes. Sales grew 83.4% last year.
Does it make a profit?
−19.3%
No. It lost money last year.
Does profit turn into cash?
−18.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
What Tempus AI does
Tempus AI runs medical laboratories and a large database of patient health data, mostly in cancer care in the United States. Doctors order its genetic and other lab tests to help choose treatments for patients, and Tempus links the results to patients' medical records and uses artificial intelligence, or AI, to put them in context. It gets data through connections with more than 5,000 hospital and clinic sites that order its tests, and strips out personal details before using it in its other products. Tempus has two product lines. Diagnostics, its testing business for cancer treatment and inherited cancer risk, brought in $955.4 million of its $1,271.8 million in 2025 revenue. Data and applications licenses that de-identified data to drug companies for research, helps them find patients for clinical trials, and sells AI tools that flag patients who may need care.
Biggest risks, in its own words
- A history of losses: it may keep losing money and need to raise more capital.
- Its reliance on continued access to patient data, and its ability to earn money from it.
- Insurers and government health programs that may not cover its tests or pay enough for them.
- Changing rules on lab tests and on health data privacy that could raise its costs or limit its products.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- Tempus AI, Inc.
- CIK
- 0001717115
Tempus AI · TEM
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | $321M | $532M | $693M | $1.3B |
| Revenue growth | — | 65.9% | 30.4% | 83.4% |
| Operating margin | −82.8% | −36.9% | −99.7% | −19.9% |
| Net income | −$290M | −$214M | −$706M | −$245M |
| Net margin | −90.4% | −40.3% | −101.8% | −19.3% |
| Diluted EPS | −$5.30 | −$4.20 | −$6.23 | −$1.41 |
| Cash | ||||
| Cash from operations | −$168M | −$214M | −$189M | −$218M |
| Capital expenditure | $18.4M | $34.6M | $22.1M | $21.0M |
| Free cash flow | −$187M | −$249M | −$211M | −$239M |
| FCF margin | −58.2% | −46.8% | −30.5% | −18.8% |
| Dividends paid | $5.6M | $5.6M | $5.6M | $0.0M |
| Share buybacks | $0.0M | $3.6M | $0.0M | $3.0M |
| Share count change | — | 0.4% | 89.3% | 45.4% |
| Debt and strength | ||||
| Cash and short-term investments | $303M | $166M | $341M | $605M |
| Debt incl. finance leases | — | $193M | $168M | $209M |
| Shareholders' equity | −$1.1B | −$1.4B | $56.3M | $491M |
| Current ratio | — | 1.5x | 2.3x | 3.1x |
| Interest coverage | −12.1x | −4.2x | −12.9x | −3.6x |
| Returns and quality | ||||
| Return on equity | — | — | — | −89.5% |
| Piotroski F-score | — | — | — | 5 |
| Altman Z'' | — | −10.8 | −9.9 | −1.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$221M
11 insiders
Of sales under plans
93%
$206M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Tempus AI · TEM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Tempus AI TEM | $13.4M | 83.4% | −19.9% | −18.8% | — | — | 5 |
| Sotera Health SHC | $5.3B | 5.7% | — | 12.8% | 6.7% | 32.3x | 7 |
| Addus HomeCare ADUS | $2.2B | 23.2% | 9.7% | 7.3% | 9.4% | 21.2x | 5 |
| Lifestance Health LFST | $5.1B | 13.9% | 1.7% | 7.7% | 1.2% | 100.5x | 7 |
| CorVel CRVL | $4.3B | 7.0% | — | 11.5% | — | 37.6x | — |
KIRA
At $67.16 a share, the company is worth $13.4M.
Tempus AI grew sales faster than 4 of its 4 similar companies.
Source: SEC EDGAR XBRL filings (CIK 0001717115). Data updated October 11, 2026. For information only — not investment advice. Check the original filings before relying on any figure.